Ersöz Gonca1. 1. Biology Department, Faculty of Arts and Sciences, Bülent Ecevit University, İncivez/Zonguldak, Turkey.
Abstract
BACKGROUND: 5-Lipoxygenase is an enzyme involved in the synthesis of leukotriene eicosanoids from arachidonic acid. The therapeutic potential of zileuton, an inhibitor of 5-lipoxygenase, and montelukast, a cysteinyl leukotriene receptor antagonist, for the treatment of ischemia/reperfusion (I/R) injury of the heart has been proposed in a few studies. However, the effects of zileuton and montelukast on I/R-induced arrhythmias have not been determined. OBJECTIVE: We assessed the possible protective effects of zileuton and montelukast against I/R-induced arrhythmias. METHODS: Forty-five male Wistar albino rats were divided into 5 groups, each containing 9 rats. Group 1: control, Groups 2 and 3: rats treated with montelukast (10 and 30 mg/kg IP); and Groups 4 and 5: rats treated with zileuton (1 and 3 mg/kg IV) 15 minutes before the induction of ischemia. Ischemia and reperfusion were induced by occluding the left main coronary artery of anesthetized rats for 6 minutes followed by reopening the artery for 6 minutes. RESULTS: Both doses of zileuton decreased the mean [SE] arrhythmia score (zileuton 1 mg/kg: 1.4 [0.8]; zileuton 3 mg/kg: 1.3 [0.5] vs control: 2.9 [0.3]; P < 0.05), the duration of ventricular tachycardia, and the total length of arrhythmias, but montelukast was not effective to decrease the ventricular arrhythmias during the 6 minutes of reperfusion. CONCLUSIONS: The results indicate for the first time that zileuton exerts an antiarrhythmic effect at different doses and that montelukast is not effective against I/R-induced arrhythmias. These results indicate that zileuton may be a candidate for drug treatment of I/R-induced arrhythmias.
BACKGROUND:5-Lipoxygenase is an enzyme involved in the synthesis of leukotriene eicosanoids from arachidonic acid. The therapeutic potential of zileuton, an inhibitor of 5-lipoxygenase, and montelukast, a cysteinyl leukotriene receptor antagonist, for the treatment of ischemia/reperfusion (I/R) injury of the heart has been proposed in a few studies. However, the effects of zileuton and montelukast on I/R-induced arrhythmias have not been determined. OBJECTIVE: We assessed the possible protective effects of zileuton and montelukast against I/R-induced arrhythmias. METHODS: Forty-five male Wistar albino rats were divided into 5 groups, each containing 9 rats. Group 1: control, Groups 2 and 3: rats treated with montelukast (10 and 30 mg/kg IP); and Groups 4 and 5: rats treated with zileuton (1 and 3 mg/kg IV) 15 minutes before the induction of ischemia. Ischemia and reperfusion were induced by occluding the left main coronary artery of anesthetized rats for 6 minutes followed by reopening the artery for 6 minutes. RESULTS: Both doses of zileuton decreased the mean [SE] arrhythmia score (zileuton 1 mg/kg: 1.4 [0.8]; zileuton 3 mg/kg: 1.3 [0.5] vs control: 2.9 [0.3]; P < 0.05), the duration of ventricular tachycardia, and the total length of arrhythmias, but montelukast was not effective to decrease the ventricular arrhythmias during the 6 minutes of reperfusion. CONCLUSIONS: The results indicate for the first time that zileuton exerts an antiarrhythmic effect at different doses and that montelukast is not effective against I/R-induced arrhythmias. These results indicate that zileuton may be a candidate for drug treatment of I/R-induced arrhythmias.
Authors: Barbara Sokołowska; Jerzy Dropinski; Marcin Rzeszutko; Wojciech Szczeklik; Marek Sanak; Andrzej Szczeklik Journal: Int J Cardiol Date: 2010-12-03 Impact factor: 4.164
Authors: T Genovese; A Rossi; E Mazzon; R Di Paola; C Muià; R Caminiti; P Bramanti; L Sautebin; S Cuzzocrea Journal: Br J Pharmacol Date: 2007-12-03 Impact factor: 8.739
Authors: Ovidiu Horea Bedreag; Alexandru Florin Rogobete; Mirela Sărăndan; Alina Cradigati; Marius Păpurică; Oana Maria Roşu; Corina Maria Dumbuleu; Dorel Săndesc Journal: Rom J Anaesth Intensive Care Date: 2014-10
Authors: Ira S Rostevanov; Batya Betesh-Abay; Ahmad Nassar; Elina Rubin; Sarit Uzzan; Jacob Kaplanski; Linoy Biton; Abed N Azab Journal: Front Immunol Date: 2022-09-06 Impact factor: 8.786